Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
February 10, 2022
Earnings Call Speaker Segments
Nick Rolli
executiveGood day, and I appreciate everyone taking the time to be with us. We put out a news announcement earlier today that lays out in depth the particulars of how we performed in 2021's fourth quarter and across the entire year. That document is available for you at www.pmi.com. Toward the close of today's webcast slides — which you'll find posted on our site — you'll see a glossary covering terminology such as the meaning we assign to reduced-risk products, or RRPs, plus adjustments, other computations and bridges back to the closest equivalent U.S. GAAP figures, along with extra data on heated tobacco unit market share. Whenever we mention IQOS without saying otherwise, we mean our heat-not-burn offerings under that brand, and whenever we mention smoke-free products, we mean our RRPs. The growth percentages we show on an organic footing are based on results that exclude currency movements. After bringing Fertin Pharma, OtiTopic and Vectura Group into the company through acquisitions, PMI introduced the other category during 2021's third quarter. The way that other category performs commercially gets assessed on its own, apart from the geographic operating segments. Remarks we're making right now include forward-looking statements along with projections about what's ahead. I'd ask you to look at the disclosure about forward-looking and cautionary statements found in today's presentation and press release, which walks through the many things that might lead actual outcomes to wind up materially different from what our projections or forward-looking statements suggest. Kindly also take note of the extra forward-looking and cautionary statements tied to COVID-19; at this point I'm delighted to bring in Jacek Olczak, who serves as our Chief Executive Officer, and Emmanuel Babeau, who serves as our Chief Financial Officer. Jacek, the floor is yours.
Jacek Olczak
executiveThank you, Nick, and greetings to everyone. I hope you're all doing well. 2021 saw our company deliver an outstanding performance, with records set for net revenues, adjusted diluted EPS, and cash flow, alongside increases in total volumes, organic net revenue growth reaching the high single digits, and adjusted EPS growth hitting strong double digits. This demonstrates the durability of our growth, which rests on new products and innovation, as the continued momentum of IQOS shows, with RRP net revenues achieving 31% organic growth for the full year. During Q4, smoke-free products represented over 30% of total net revenues, advancing us toward our goal of becoming a predominantly smoke-free company by 2025. Q4 brought a nice pickup in momentum that beat what we'd been looking for, and that was especially gratifying. You could see that pickup across several areas: organic net revenues, the number of IQOS users, heated tobacco unit market share in established and developing markets alike, new devices and consumables, plus commercial spending and combustible share. IQOS user counts recovered during Q4, hitting roughly 21.2 million in total, despite device supplies staying constrained through the back half of the year. Looking at the whole year, heated tobacco unit shipment volumes climbed 25%, landing at 95 billion units, and growth was widespread for our volumes and for the category across major geographies, with the EU in particular posting a strong bounce-back. IQOS's growth prospects remain highly encouraging. We've seen excellent early performance for IQOS ILUMA in Japan and Switzerland—the only two markets where it's launched thus far—and IQOS VEEV is gaining momentum in its initial launch markets. On the combustibles side, we basically hit our target of a steady category share in Q4, even with the drag from IQOS cannibalization. Over the course of the year, we built the groundwork for our long-term ambitions outside nicotine, in Wellness and Healthcare, highlighted by the landmark acquisitions of Fertin and Vectura, which give us critical capabilities for developing future products. Lastly, supported by robust operating cash flow, we kept shareholder returns a priority, raising the dividend by 4.2% and continuing our share buyback program. Now for the top-line results. For the whole year, adjusted net revenues were up 7.6% on an organic basis, and 10.3% when measured in dollars, helped by favorable currency movement. That performance shows IQOS remains fundamentally strong, and combustible products kept bouncing back across numerous markets relative to the prior year, which had been hit by the pandemic. Net revenue for each unit sold rose 5.3% organically, lifted by a larger share of IQOS within our sales mix as well as by pricing. On combustibles, pricing landed where we had expected, at 2.7%, or roughly 4% once Indonesia is excluded. Our adjusted operating income margin came in 200 basis points higher organically, matching what we had forecast, as we continued to benefit from IQOS getting bigger and more profitable, from pricing, and from productivity savings. For the first six months, we saw growth — though that robust first-half performance was partly offset later in the year by several factors: the anticipated higher initial per-unit cost of IQOS ILUMA, investments in expanding geographically and across categories, and the return of consumer programs in various markets during Q4. Adjusted diluted earnings per share reached $6.08, representing an increase of 17.6% in dollar terms and 15.3% on a currency-neutral basis. This outcome exceeds the guidance we had provided earlier, driven by IQOS user gains, the Illuma rollout, and industry volumes overall all surpassing our expectations. Wrapping up, operating cash flow came in at $12 billion. That reflects excellent cash conversion at the core, plus a strong Q4 performance and certain timing factors. Moving to our Q4 results, organic net revenues were up 8.4%. That figure reflects the quarter-over-quarter improvement in IQOS user acquisition, ILUMA's encouraging start in Japan, and healthy volumes across the board, helped by further recovery in combustibles. Organic net revenue per unit grew a solid 4.1%, again demonstrating the impact of our shifting business mix. We achieved this despite a 1.4% decline in combustible pricing, which stemmed from the issues we previously highlighted: continued pandemic-driven challenges in select markets, along with comparative effects in Germany and Australia. During Q4, our organic adjusted operating income margin dropped by 10 basis points, largely because of the same factors mentioned for the second half, since improved business results gave us greater capacity to put money into future growth. Nevertheless, our adjusted diluted EPS on a currency-neutral basis rose sharply again, increasing 11.9%, which also reflects reduced interest expense and a lower effective tax rate. Now let me turn to the 2022 guidance. After IQOS user growth experienced a temporary deceleration in the latter half of 2021, the supply situation for devices is gradually improving. Although conditions remain in flux, we currently expect a smaller hit, so we can steadily return to prior levels of user growth over the next several quarters. Because ILUMA performed exceptionally well in its initial market, we have multiple other innovations in development, and IQOS shows encouraging expansion in low- and middle-income countries, the underpinnings of our 2022 growth remain solid, and we anticipate a dynamic year. Keep in mind that decelerating user gains during the latter half of 2021, particularly in the third quarter, are projected to produce a carryover impact on this year's growth of roughly 4 billion to 5 billion cubic tobacco units. That's reflected in what we're projecting for 2022: H2 shipment volume somewhere between 113 million and 118 billion. Given that ongoing expansion, we anticipate our H2 shipments for the entire year will beat IMS volumes yet again. On organic net revenue growth, we're looking at delivering somewhere in the 4% to 6% range, which keeps us firmly on course toward our target of a compound annual growth rate above 5% for 2021 to 2021, 2023. That range sensibly takes into account the persistent uncertainty regarding full device availability as well as how quickly the pandemic recovery continues. When it comes to Duty Free, our assumption is that Asian travel won't see any meaningful pickup, while other geographies keep recovering gradually. Looking ahead, we see our adjusted operating income margin widening by 50 to 150 basis points, driven by the ongoing benefits of the changes we've made to our product lineup, even though we're bracing for gross margin to come in somewhat lower. What's behind that largely boils down to near-term factors connected to ILUMA — specifically, the heavier initial weighting and cost of TEREA consumables, plus what the devices themselves cost. Over the 18 to 24 months after launch, we expect those to ease, exactly as happened with earlier — with earlier major innovations. We're also factoring in elevated logistics expenses, since the enormous adoption of ILUMA in Japan has driven more reliance on air freight, investments to expand capacity throughout our smoke-free platforms, and inflation in some supply chain components. Our continuing efficiency initiatives will once more underpin operating income margin expansion as well as ongoing growth possibilities, plus wellness and healthcare R&D; we're still set to achieve roughly $2 billion in gross savings by 2023. So we project currency-neutral adjusted diluted EPS growth between 8% and 11%, which works out to an adjusted diluted EPS range from $6.12 to $6.30, factoring in an anticipated unfavorable currency hit of about $0.45 at prevailing rates. The primary factor at play is how currency translation is affecting things, and that foreign exchange effect specifically reflects the euro, Japanese yen and Turkish lira gaining value relative to the dollar. Built into this outlook is the impact from $785 million in buybacks carried out during 2021, which were constrained somewhat by blackout periods.
Jacek Olczak
executiveThis doesn't account for the effect of buybacks made during 2022, since we keep taking an opportunistic stance as we aim for somewhere between $5 billion and $7 billion across three years. The outlook we're providing also incorporates the businesses we've acquired, and we anticipate those will deliver underlying operating income consistent with our business plan, though they'll bring an operating loss of roughly $150 million, or about 1% of adjusted diluted EPS — a topic we'll return to and clarify shortly. As today's release lays out, several other assumptions support our forecast. We project that total industry volume for cigarettes and to cubic tobacco units, leaving out the U.S. In China, the figure is expected to land between negative 1% and negative 2%. Thanks to our leadership in smoke-free products, the structural expansion of that category, and the growing portion it represents of our overall business, we expect to gain share, with total PMI shipment volumes aimed at roughly flat, somewhere from negative 1% to positive 1%. Looking at the whole year, we're modeling combustible pricing between 3% and 4%, softer in the first half and firmer in the second; clearly, that sits above 2021's level. Although the pricing environment is improving, conditions stay challenging across central markets given the ongoing effects tied to the pandemic. Our balance sheet remains healthy. For 2021, we delivered exceptional cash flow from operations totaling $12 billion. That result came from robust cash conversion in the business, plus helpful timing, and a nonrecurring benefit of about $0.5 billion. As we move into 2022, we expect continued strong organic profit growth, and we aim to produce approximately $11 billion in operating cash flow. That figure depends on working capital requirements at year-end, and it accounts for the reversal of those timing advantages, using current exchange rates. Because of this, we raised the operating cash flow goal for 2021 through 2023. That target, originally shared at the February 2021 Investor Day, stood at $35 billion, and we have now increased it to a range of $36 billion to $37 billion. For the entire year, we're looking at capital spending of roughly one billion dollars. That figure covers bigger investments in capacity for our smoke-free products, including ILUMA, along with efforts to bolster our digital commercial engine, and it also accounts for some projects that got delayed because of the pandemic. Now, focusing on Q1 of 2022 specifically, we're expecting adjusted diluted EPS between $1.50 and $1.55. That range factors in $0.15 of currency headwinds based on current rates. On the top line, we're anticipating solid organic growth, and for operating margins, the comparison is against an exceptionally strong quarter a year ago — one that gained from significant productivity savings and fairly light investment levels — while Q1 of 2022 brings commercial spending, ILUMA related expenses, and higher costs for certain inputs like freight. I'll now pass things over to Emmanuel, and he'll walk you through additional specifics regarding how we did in 2021.
Emmanuel Babeau
executiveThanks, Jacek. Let's go back to how we performed in 2021. Our overall shipment volumes were up 4.2% in the fourth quarter and up 2.2% across the entire year. That shows the broad-based growth from HTUs stayed strong, rising 25%, which equals 18.9 billion units for the full year, and that comfortably outweighed a decline of 3.6 billion cigarettes. Cigarette volumes in Q4 rose 2.4%, which reflects how both the total industry and our category share kept recovering sequentially, plus a favorable inventory movement of 2.7 billion sticks, mostly because of inventory reduction in the same quarter a year earlier. Thanks to IQOS performing so remarkably, inter tobacco units made up nearly 14% of total shipment volume during the fourth quarter and 13.2% for the year, compared with 11% for all of 2020, 8% in 2019 and 5% in 2018. Our sales mix is shifting quickly, which keeps us on track to turn into a majority smoke-free company by 2025. Smoke-free net revenues accounted for more than 30% of adjusted total revenue in Q4 and 29% for the year, versus 24% in 2020. In 10 markets, we are already above 50%. IQOS devices represented more than 6% of the $9.1 billion in 2021 RP net revenues, with an acceleration in H2 tied to the IQOS ILUMA launch that more than offset the impact of supply constraints on the IQOS versions. We posted 7.6% organic growth in 2021 net revenues alongside shipment volume growth of 2.2%, which shows the twin engines behind our top line. The first engine is pricing on combustible products and, in some markets, on HTUs. The second is a growing share of HTUs in our business at higher net revenue per unit, which keeps producing substantial growth and becomes an ever more powerful driver as our transformation speeds up. Now let's look at what drove our 2021 margin expansion. Gross margin rose 190 basis points organically thanks to product mix, pricing and cost savings, while adjusted marketing, administration and research costs came in 10 basis points better as a percentage of adjusted net revenues; we produced more than $800 million in gross cost savings in 2021, with roughly $550 million from manufacturing and supply chain productivity and over $250 million from SG&A efficiency before inflation. That marks solid progress toward our target of about $2 billion for 2021, 2023 and lets us reinvest in top line growth while still delivering strong margin progression. Although OI margin expansion was smaller in H2, that mirrors the positive dynamics of our business and our capacity to bring investment back to normal levels relative to the prior year, which the pandemic had affected. ILUMA device and HTU shipments began with higher initial unit cost, and we stepped up investments again in our commercial program, digital engine and R&D, along with a number of growth opportunities spanning categories and geographies; we plan to keep investing in those opportunities in 2022. Yet thanks to scale advantages, operating leverage, and faster efficiency gains, we still aim for organic SG&A growth that stays under the pace of sales expansion. Turning to market share now. Our portion of the combustible segment bounced back and ended Q4 roughly flat versus the same period a year earlier, since portfolio programs are paying off and pandemic-related curbs were eased across numerous geographies. Being the leader in combustible supports getting as much switching as possible into smoke-free offerings, and over the longer term we keep aiming for a steady category share even with IQOS cannibalization weighing on it. Beyond consumer expansion, which we are speeding up, we are initially targeting a slight drop in 2022; across the combustible category as a whole, the better total market environment features significant Q4 rebounds in Indonesia, Mexico, and Turkey, industry volume in the EU region that is close to flat, and a small recovery in duty free powered by sales beyond Asia. In some markets, like the Philippines, daily usage is still under the pre-coded level, and there our market share is shaped by mobility and social consumption; in Indonesia, our share once more was broadly unchanged sequentially even as the below Tier 1 segment kept expanding, and our volumes climbed more than 4% across the year. Cutting the excise tax year from 10 to 8 in 2022 is a move in the right direction, and the industry weighted average excise hike of roughly plus 13% sits a bit under the previous year. Still, the competitive field stayed uneven among industry players, and pricing conditions continue to be difficult; regarding our overall share, continuing gains from our IQOS portfolio build positive momentum as we enter this year, and we anticipate resuming overall share growth while also delivering broadly steady total shipment volume. PMI HTUs currently hold a 7.1% share in the markets where they are sold, which makes them the third largest tobacco brand. That covers the top spot in five markets, plus second place in six additional markets. Shifting to IQOS performance now. We estimate roughly 21.2 million IQOS users existed as of December 31. The stronger growth of plus 0.8 million during Q4 shows how our agile commercial model let us quickly tweak our consumer program and assortment. As ILUMA's results in Japan and Switzerland show, the fundamental momentum behind the IQOS brand is still solid. Although we lack full visibility into all of 2022 at this point, once device shortages lessen, we anticipate a gradual return to user growth at or above the earlier run rate of about 1 million per quarter. We estimate 72% of all users, or 15.3 million adult smokers, have switched to IQOS and quit smoking, with the rest at various stages of conversion. Within the EU region, fourth quarter HTU share hit 6.4% of total cigarette and HTU industry revenue, which is 1.4 points above Q4 last year. The fundamental IMS growth trajectory continues to look very strong. That solid result featured robust expansion throughout the region, with Italy hitting the 2 million user mark and favorable contributions coming from Germany and Poland. I'd also like to call attention to Hungary, where our national HTU share in Q4 came in above 20%, joining Japan and Lithuania in crossing that significant threshold. To add a bit more detail regarding how we're doing in the EU region, this slide presents a sampling of the most recent key city offtake shares. Vilnius kept its leading position at 37.5% share, while the 20% mark was likewise attained in Budapest, Rome and Athens. Given the strong momentum throughout the region, we're particularly encouraged by Vienna, which nearly doubled to 4%, by the robust traction in London at close to 6% share, and by an acceleration in Zurich tied to the launch of IQOS ILUMA. Additional HTU share figures appear in the appendix to these slides. Share gains carried on in Russia, where our Q4 TU share rose by plus 0.8 points to hit 8%. For Russia specifically and for the region as a whole, sequential growth in adjusted IMS decelerated over the past two quarters, which partly mirrors the more severe device shortage and the lead on the commercial program. Beyond that, the region felt the effects of sales being halted in Belarus, which weighed on sequential IMF growth in Q4; against that backdrop, as we noted last quarter, we've observed a rise in discounted competitor offerings as well as disposable e-vapor products.
Emmanuel Babeau
executiveWe keep observing significant enthusiasm for this segment, and thanks to a lineup of thrilling new products we have planned, such as the introduction of ILUMA, our goal is to return to robust expansion during this year. Turning to Japan, the adjusted total tobacco share held by our HTU brands rose by 1.7 points, reaching a record 21.8% during Q4. Additionally, offtake exit share is nearing 23%, reflecting Q4 adjusted IMS sequential patterns, which factor in the earlier consumer uptake pulled into Q3 ahead of the price rise. These results demonstrate how solid our portfolio is and highlight the debut of IQOS ILUMA, a topic I will revisit soon. The heated tobacco segment overall keeps expanding, accounting for more than 31% of the adjusted total Japanese tobacco market during Q4, while IQOS holds a substantial portion of the segment and secured most of the category's growth for 2021. Beyond the robust advances in developed nations, we are witnessing highly encouraging IQOS expansion in low and middle income markets. A standout illustration is Egypt, where offtake share in Cairo is nearing 4% just six months after introduction, alongside other significant wins such as Lebanon, Jordan, the Dominican Republic and the Philippines, even with funding being retracted in Manila. This key city performance across low and middle-income markets is particularly heartening since we accomplished it despite the premium positioning of the existing IQOS lineup; we do plan to introduce a fresh complementary array of heat-not-burn items designed for emerging markets near the close of this year, which I will revisit. Keeping this potential in view, we keep pushing forward with geographic expansion of our smoke-free items as we target being present in 100 markets by 2025. Throughout the quarter, we introduced IQOS in Morocco as well as Tunisia. This brings the overall count of markets where PMI smoke-free items can be purchased to 71, with 30 of those being low and middle-income markets. We intend to add additional markets this year while also substantially widening our product range and price segmentation in areas where we already operate. This encompasses growing feel and feet, which are currently offered in more than 20 markets spanning various regions, plus our growth in e-vapor and nicotine pouches. After the ITC's importation ban took effect, IQOS is presently unavailable in the U.S. We keep working on backup strategies, such as manufacturing domestically, and aspire to restore U.S. supply during the first half of 2023; it's crucial to recall that the ITC's ruling on this patent is an anomaly. We took encouragement from the U.S. patent office's recent invalidation of one of the two patents involved in the ITC decision, and we anticipate a ruling on the second patent by April 2, even though this ruling could be appealed. BAT has failed across the board in enforcing those same two patent families against IQOS throughout Europe. Also in December, a court in Germany determined that BAT's GLO HYPER dual-coil heat-not-burn product violates our patents, and that we are entitled, among other things, to an injunction blocking BAT's sales cells of that device. Turning next to IQOS ILUMA. Since its introduction in Japan and Switzerland, we're thrilled to share that results have been exceptional, with sales figures and consumer response surpassing what we expected. Since ILUMA became available in August, uptake in Japan has moved quickly — both among people already using IQOS and among smokers of legal age. More than a fifth of that large existing customer group has already made the change, and over 20% of purchases come from legal-age smokers via IQOS. On top of that, the better and consistently strong experience for users, along with greater dependability and the fact that no cleaning is needed, has led to clear improvements we've seen in conversion, retention, and Net Promoter Score. That signals we're set for substantial growth in volume. Actually, TEREA consumables, which sit at a premium price point, have turned into the quickest-expanding launch within the small free category. Within three months of going national, they reached an offtake share of 8% across the three major convenience store shares change, and they've also driven expansion of the heat-not-burn category following the price hike tied to taxes in October. Over in Switzerland, the early numbers look even better: more than one-third of sales are coming from new users, and TEREA represents over one-third of HD sales after only two months on the market. In connection with that, our HTU share gain accelerated, rising from 6% in September to 7.9% in December. We find these figures very encouraging for expanding ILUMA more widely across the EU and around the world, and our plan is a gradual introduction into further markets during this year, chiefly in H2. Even as we continue to handle limits on device supply, the extraordinary expansion seen in Japan has also forced us to accelerate airfreight shipments of the TEREA consumable as well as the retooling of our production line so that new market launches can be supported. Thanks to ILUMA, IQOS 3 DUO and LIL, the IQOS family now encompasses three heat-not-burn technologies, allowing us to meet varied consumer requirements and divide the market into segments. Our innovation pipeline looks exciting, spanning devices and consumables, with offerings at a range of price points. Like I said, we're also getting ready to strengthen what we offer so we can grow down the road, and that includes bringing out a brand-new complementary technology near the end of this year. It's aimed at people who smoke in low and middle income markets, and it speaks to what those consumers want: devices and consumables that are straightforward, high-quality, and affordable, along with test performances tailored to specific locales. On the HTU side, we rolled out more than 15 new ILUMA SKUs during Q4, and this year we intend to keep broadening our lineup across platforms, geographies, and price points. Meanwhile, we're still commercializing IQOS VEEV, and the early results are quite encouraging in that first set of markets, where we began in our own channel with a limited selection of test variants and nicotine levels. IQOS VEEV is a premium offering that delivers a better experience, and because the IQOS commercial engine moves faster, we can roll out efficiently and leverage our scale via a tailored route-to-market strategy. As we begin widening distribution along with the consumable range, we've noticed indications of rising uptake and plainly favorable feedback from consumers when compared with rival products. In Italy and the Czech Republic we're seeing encouraging success, hitting double-digit offtake shares at nearly 10 points, with swift gains also apparent in Croatia inside three months from launch. Having introduced the product in Canada and Ukraine during the fourth quarter, we intend to bring in additional markets during 2022, though the schedule depends on device supply. We likewise kept up preparations to seek a PMTA from the U.S. FDA and now take the prudent view that we'll be ready to file in early 2023, since we have more clarity regarding the necessary preparatory steps. Another compelling midterm growth avenue lies in the nicotine pouch segment, where we intend to become a top-tier participant with a Shiro brand. Nicotine pouches offer a handy smoke-free option for adult smokers. And though it's still early days across many markets, we expect Shiro to serve a significant role within our smoke-free portfolio in the years ahead. After purchasing AG Snus and Fertin Pharma, we've built a foundation of expertise in product development and manufacturing. Even as we continue to learn about this promising category, our IQOS commercial infrastructure enables a swift rollout, and we're planning several launches across the upcoming quarters.
Emmanuel Babeau
executiveKicking off with the biggest item: we're bringing the revitalized Shiro lineup to the Nordic market this month as a full commercial re-launch. Before, it had only a limited presence there. Now it's a complete commercial push with a wide range of flavors and different strengths. On a separate note, after what we heard from the 2021 consumer test on our Platform 2 carbon product, we've stopped the design of the technology we currently have. We're looking at a different design for that consumer segment. Now shifting to our early-stage business outside nicotine: the 2021 purchases of Fertin, Vectura and OtiTopic give us the foundation to build essential respiratory and broader product development skills alongside what we already know. That created a chance to bring the beneficial effects of existing wellness and health care molecules to people quickly and effectively. At this point, what we report in the other segment reflects the acquired business as it stands, which brought in $101 million of net revenue during the fourth quarter and posted a marginal operating loss of $1 million. Underlying performance matches what we anticipated, and reported operating expenses capture the amortization of intangibles, deal-related items and the investments we've planned. Roughly 39% of Q4 revenue came from Fertin's smoking cessation product plus nicotine pouch operations. We do plan to keep up the CDMO work of the companies we acquired, but for PMI the greatest value lies in being able to develop and commercialize new products in wellness and healthcare down the road. Over the next several years we intend to make significant R&D investments to help reach the goal of meaningful incremental revenue beginning two to three years from now, as we chase our ambition of at least $1 billion in net revenue from wellness and healthcare products by 2025. As I said before, we're expecting an operating loss of about $150 million in 2022, on revenue of roughly $250 million, smoking cessation products included; we've noticed investor interest in our future product line in these new areas and we plan to offer more color at our CAGNY conference presentation on February 23. Switching to sustainability and our ESG priorities, I'm glad to report that we just finished a fresh sustainability feasibility assessment to refresh and recalibrate our priorities based on where we have the biggest impact on society, double maturity and extensive stakeholder inputs. Dealing with the health impact of our product stayed far and away the largest focus, but we also pinpointed a number of topics that are growing in importance or needed a different approach. Next week we'll publish the results; aligning management incentives with sustainability materiality, performance and impact matters more and more; we'll reinforce that connection in 2022 through the new sustainability index and plan to share more details soon. Leading external stakeholders keep acknowledging our sustainability progress, with repeated inclusion in both the Dow Jones Sustainability Index North America and the Bloomberg Generic-Quality Index, plus CDP's AAA score for the second year running. We put out a report on agricultural labor practices as well, which commemorates a decade of that initiative. From the time it began, we've managed to wipe out the systemic problem involving child labor, and at the same time we've made life better for farmers and farm workers. That report also laid out our aspirational goals, for instance having 100% of farmers who supply tobacco to PMI, generating leasing income by 2025. When it comes to our top priority of product impact, the rising uptake of smoke-free products globally is speeding up the demise of cigarettes as legal-age smokers move to better options. I'm happy to share news of additional favorable regulatory progress lately; for instance, within its beating cancer plan, the European Parliament special committee acknowledged and highlighted harm reduction in its latest report, with the plenary vote scheduled for next week. Over in New Zealand, the government released its more action plan, which explicitly leaves small free product out of the proposed measures. Beyond that, a number of countries, Poland and Russia among them, have rolled out new multiyear excise tax plans where taxation of smoke-free products is clearly set apart from cigarettes, bringing the total to 15 markets worldwide with such plans. Scientific and real-world evidence keeps accumulating regarding the considerable reduction potential that smoke-free product offers relative to smoking. Though difficulties in certain markets should be anticipated, we keep backing regulatory and fiscal frameworks that acknowledge this vital harm reduction opportunity. Now I'll hand things back to Jacek for a few closing remarks.
Jacek Olczak
executiveThank you, Emmanuel. All in all, we're quite happy that we achieved outstanding expansion during the previous year, 2021, driven by robust fundamental momentum for IQOS, alongside record adjusted EPS, net revenues, and cash generation. The steady quality and durability of our organic performance on both the top and bottom lines has been plainly shown across the past 2 years, something I think all of us recognize with pretty to volunteers. As the device supply outlook improves — though some degree of agility is still required — combined with ILUMA's remarkable early triumph and the many innovations and growth initiatives, we anticipate 2022 with enormous enthusiasm. Simultaneously, we are creating — we will create our development capabilities in wellness and healthcare for focused investment, so as to underpin the next engine of our long-term growth. Our balance sheet remains solid, and we've boosted cash returns to shareholders via a larger dividend and our share repurchase program, consistent with our aim of providing sustainable value and returns to investors as we proceed with our smoke-free transformation. In brief, we still foresee a promising future for our business. After a very robust 2021, we stay confident in our '21 to '23 growth targets and in our ambition to be majority smoke-free by net revenues in 2025. Thank you everyone for listening. Emmanuel and I will gladly take your questions.
Bonnie Herzog
analystHello, Jacek and Emmanuel. Trust things are going nicely for both of you. My question concerns the EPS outlook you've given for this year; on a currency-neutral basis it spans 8% to 11%, which is fairly wide; so could you point out which main assumptions or drivers would land you perhaps at the bottom of that span, versus what would have to occur for you to reach 11% growth? For example, could 11% still be achieved even if the chip shortage isn't sorted out over the coming months?
Jacek Olczak
executiveI believe that's Emmanuel.
Emmanuel Babeau
executiveI'll take this one. So clearly, as we mentioned in our opening comments, there are still quite a few unknowns we're dealing with. Even if the situation appears to be getting better, COVID hasn't gone away. We lack complete clarity regarding the IT shortage as well as global supply chain issues. That is plainly what's driving a certain amount of caution behind the top-line guidance we're providing. From that point, naturally, we're running a business that's experiencing solid momentum; we have the usual price increase driver. We'll be extremely effective when it comes to cost savings. You can look at what we delivered during 2021 — already over $800 million in cost efficiency. We'll keep going in 2022; and I know that will create the gap between revenue growth and adjusted EPS organic growth. One headwind we'll encounter this year, which I believe ought to be viewed as quite positive since it stems from growth, and we're handling a very attractive growth potential, is that we're making investments for an exciting outlook. It begins, naturally, with ILUMA in Japan, but on a global scale, the ILUMA launch, though certainly with a major effect in Japan, where we know that launching a new product carries some consequence for cost of goods since we aren't at the same efficiency level within the supply chain. Productivity hasn't reached its peak, and we've covered that in our comments. That will create some impact at launch. We mentioned air freight too, and that is going to have an effect. We stated it with, probably, what we observe today being a moderate decline in the gross margin rate. Absent that, based on what we see today, it would have been another year of gross margin rate growth; but that's genuinely what's behind the guidance; so there's some uncertainty, yet we're very thrilled by the growth potential we see from all this innovation coming through. We have the usual efficiency driver that will assist; we have a headwind, which was entirely anticipated since we're bringing innovation, and we must invest to launch that innovation. And I should mention regarding innovation, though it's certainly the reality that we're also broadening geographically — what we're seeing in Egypt signals extremely well for the potential across emerging countries, but we must invest, naturally, to build capacity; we must develop our commercial tools. We must invest in the new platform, vaping and nicotine pouches. What I find really positive about this guidance and about what we're aiming for in 2022 is that while it's a year carrying a lot of investment for exciting growth, we can still turn in a solid, dynamic top line. We can turn in a pleasant margin improvement, solid organic growth at a solid level; and as you've noticed, we generate an enormous amount of cash, and we accomplish that simultaneously, once again, while putting money into the future.
Bonnie Herzog
analystAlright. That's really useful, and to be honest it makes perfect sense. So obviously there are plenty of pluses and minuses here, but you have plenty of options available. For my second question, I thought I might shift topics a little and just ask about what's going on in the U.S; and maybe get an update. From what I hear, you're expecting to re-enter the market with IQOS next year. So I'd love a bit more detail on that; and when you build out production in the U.S., will that fall on you financially? And then Altria brought up some problems between the two of you regarding your agreement in their fourth quarter press release; so I was just hoping to get a clearer picture of what that might mean. For example, I suppose, if Altria doesn't comply with the agreement's terms, would you then handle distribution of IQOS in the U.S. on your own? And/or, I guess, look for a different distribution partner? Could you sort of explain that for us? And then I'm considering a possible technical fix for VEEV in the U.S., if it gets approved.
Jacek Olczak
executiveYes. So Bonnie, we're working on the — bringing the manufacturing capacity for IQOS on the U.S. territory. So that covers our primary strategy for mitigating or responding to the situation as it stands following the ITC ruling. We've said before that by summer of next year, we expect to be able to restart shipments within the United States. Regarding ourselves and Altria — we're quite close, though there's some dispute between us over whether Altria has met specific milestones under the existing agreement. Right now we're in talks, or discussions, with Altria aimed at resolving this. I'm hopeful that, acting in good faith, we'll arrive at some solutions. Beyond that, I can't really say — anything more would just be guessing about what other paths we might take and how we'd handle IQOS in the U.S. moving forward. Look, when it comes to how things stand with our partners, my expectation is that the two sides will arrive at some kind of friendly resolution. As I've mentioned repeatedly, the situation in the United States — like a handful of other markets — involves only a tiny footprint for us, though that footprint carries strategic value. So you've clearly heard this from us before: my view is that the IQOS results in the U.S. before the ITC ruling came down... And you know, when you look at how IQOS does in all the key markets, I mean, at this point it's honestly far short of what I'd have anticipated, or of what I'd say IQOS is capable of; and when I factor in that this is an inhalable product with FDA authorization, that you basically face no rivals, plus the market's size and so on, I think it's reasonable to say expectations went well past where we stand now. Still, I'll stop there for the moment, and what I expect is that a good result will come about—one allowing American cigarette smokers to get hold of that technology, while at the same time bringing us some gain via what our partners accomplish in that space.
Chris Growe
analystFirst off, I'd like to ask about IQOS. You saw a pleasant uptick in the count of IQOS users during the fourth quarter. I'm trying to understand — and I realize you mentioned speeding up the return to roughly 1 million users sequentially. Is it impossible for that to occur before the second half of '22? Or will there be enough supply that you might begin seeing that kind of user expansion in the first half of '22? I'm simply attempting to gauge how device availability shapes the growth picture for '22.
Jacek Olczak
executiveYeah. Well, the reacceleration in Q4, getting back to the earlier pace of user growth, is quite encouraging. I've just affirmed that IQOS possessed that capacity for ongoing expansion. Naturally, this depends heavily on the reality that we enjoy unrestricted device availability. And keep in mind that IQOS now offers heat-not-burn options, which at present comprise several iterations of the IQOS blade product. I ought to bring up the real product arriving via the separate partnership involving TMG alongside IQOS ILUMA. All this also somewhat builds a certain array of offerings aimed at different targets across different consumer segments. So we recovered some flexibility to reconfigure the entire portfolio during Q4. Consequently, in Europe we all witnessed that remarkable rebound in acquiring users. This is somewhat mirrored in our 4% to 6% growth target along with the heated tobacco unit goal for this year — regarding how many months, or how many weeks within a year, we believe unrestricted access to the complete device product portfolio is possible. I think the true potential for IQOS to soar is greater when we're in that unrestricted mode, yet given what's in the product for next year, we ought to adopt a larger scenario that perhaps leans more toward the moderate side, and so on. Were it not — if we didn't face all these device-related constraints plus a few other supply chain matters, I think we'd be examining different figures; but right now, it's hard to begin treating this as something we believe we can actually deliver. So I suppose what I'm saying is IQOS holds a greater potential growth rate, but you truly must wait for the point when we can operate unconstrained. It goes without saying that a portion of our growth originates from the Asia region. And even though the European Union formed less of the piece you favor, appearing to put COVID behind it, we still aren't at that point in Japan and a handful of other places. So we must also begin accounting for this. Still, I'm quite optimistic we can deliver 2022 and, honestly, given how much headwind we must absorb in our test during 2022, I'm actually starting to feel excited about '23.
Emmanuel Babeau
executiveTo add to what was said regarding your question about hitting 1 million — I'd say we're just seeing more of a ramp-up at this point. That doesn't rule out getting to 1 million during one of the quarters in H1, though it is accurate that a ramp-up and an acceleration are what we observe as the year progresses.
Chris Growe
analystUnderstood. I have a quick additional item tied to what Bonnie asked about the U.S. Is there a scenario where the patent office review goes your way, allowing you to start importing the product again earlier than the first half of 2023? In other words, you're building up your American supply chain, but is it possible you win on the patents and find yourself able to bring the product in once more?
Jacek Olczak
executiveWell, that's the situation. But the whole thing, I think, requires distinct conversations about patent law and the various processes involved, and unfortunately, this is something we have to contend with. Look, when it comes to getting certain patents invalidated, we come out ahead — no question about that. But on the flip side, in a case like this one, they'd still have grounds to appeal. So the whole thing ends up dragging on for a very long time. And honestly, you're looking at another two years or so before either party can stand up and say they've won completely. After that, you'd have to go before the ITC and get those restrictions put in place — the ones that are being applied to us right now. My view is that, assuming nothing else gets resolved, the quickest way for us to get back into the U.S. market would be to fire up our own production here at home and start serving customers from there again. Down the road, perhaps we'll face limitations, and in that case the U.S. could be served both by overseas sources and by ones here at home. Still, what I see as our immediate opening is to take the path we already talked about.
Pamela Kaufman
analystI'd like to ask about what you expect for combustible pricing in 2022. Last year's pricing came in under your historical growth rate because of challenges in Indonesia. Could you share what you anticipate for pricing and the pricing landscape next year? Also, how do you weigh price realization against market share when it comes to combustibles?
Jacek Olczak
executiveSure. As we've mentioned, we anticipate a pricing variance of 3% to 4% in 2022, which represents an improvement over 2021. Certain Asian markets, due to a range of factors, are likely still lagging behind what we'd typically expect to achieve, at least when measured against our past trends there. You're correct that Indonesia is in negative territory, even though the industry must pass along the tax hikes. That does offer some optimism that perhaps Indonesia can get back to a point where pricing serves as a key driver of growth there. Still, we need to factor in the effects of recovery and volumes, and I'll probably focus more on the Philippines. We're assessing how much we can reverse in 2022, what gains we can secure in '22, and how quickly we can build momentum for '23. The direction is positive, though a bit more progress is required. As for the pricing environment, it's hard to forecast precisely, but our characterization is that it's getting better across all our markets. At this point, we have fairly solid visibility into the taxes in the major volume and profit markets. Emmanuel mentioned in his section that an increasing number of countries are adopting a multiyear framework, which improves our visibility and planning. In certain nations, as you're aware, tax hikes can't be fully passed to consumers all at once. You have to do some groundwork, apply some pricing beforehand and some afterward — so things are moving the right way, particularly considering that every country and market faces tremendous strain on public finances from COVID and so on. I believe we've managed that quite well so far.
Pamela Kaufman
analystAll right, thanks. For my next question, I'd like to ask about ILUMA adoption. Could you share a bit more detail regarding the extent to which ILUMA has fueled new user expansion for IQOS in Japan? Also, what have you noticed concerning this user base and how it interacts with earlier iterations of IQOS?
Jacek Olczak
executiveSure. Well — you may recall — from the moment ILUMA first launched, I personally felt tremendous enthusiasm for this innovation. And it brings me great joy that it lives up to what I hoped for; in fact, it surpasses my expectations. So, if you'll permit me, I'll keep speaking in this excited tone. Clearly, ILUMA does bring in the IQOS user — those using the Blade product — you recognize the advantage of ILUMA right away, the instant it's in your hands and you have your first encounter with it. And consumer reaction in Japan has been extraordinary. Naturally, ILUMA appeals to current users, yet we're already seeing the upside of existing IQOS users making the switch to ILUMA, since their usage stays continuous at any point during the day when they want to use the product; this likewise affects volumes. Put another way, when I hand you a device that's far more user-friendly, dependable — vastly, vastly, vastly more dependable — you'll tend to consume more compared with what you get from a blade, which we unfortunately couldn't enable you to experience. So that's a real positive. The next point is that ILUMA, following these first several months, has shown a very strong, elevated rate of conversions. And as you're aware, that's a crucial piece of the business model. The number of devices will completely convert combustible smokers into non-combustible users. How many among them will remain matters because it eases future pressure on margins, and so on. And the third point: at this point, I recall the figure is roughly 20% of ILUMA users come from individuals who were never in the category — not in cost. Moreover, what I've recently begun noticing is that you're also winning back users who had briefly switched away from IQOS to rival products. So in every dimension of ILUMA's performance, it truly excels on all fronts; thus the question remains — and I realize for some this might be a concern — do we have devices available? And can we keep supplying the market, and so forth? I believe that thus far, things are genuinely moving in the proper direction.
Vivien Azer
analystMy first question concerns pricing. It's definitely encouraging to hear that your 2022 outlook anticipates better pricing compared with last year. I was wondering, though, whether you could comment on how you think about managing the price gap between your combustible cigarettes and your heated tobacco units?
Jacek Olczak
executiveIn most markets, or indeed all of them, we basically keep IQOS positioned the same way today against the combustible reference price. As you're aware, the majority of tax systems effectively build that conversion mechanism right in. So should a combustible tax rise, that proportionally drives a rise in heated tobacco units, which means consumer price gaps stay essentially unchanged. Naturally, we supplement this depending on market conditions and our portfolio — KT&G, for instance, the real proposition — and I believe it performs really well, particularly in geographies where IQOS gets to levels above, say, premium — matching the premium price segment in combustibles; so affordability has to enter the equation too, so rather than acting on IQOS and heat pricing, we're in fact broadening the portfolio downward, and also upward in certain geographies where we see an opportunity with a bus premium versus IQOS versus heat. We carried this out very successfully in Russia and a few European markets. So I think the overall point is that the wider our portfolio stretches horizontally on price and vertically on taste, flavor, and so on, the more we keep making heat-not-burn more appealing to cigarette smokers, encouraging them to switch.
Vivien Azer
analystGreat. Then for my second question, I want to ask about the choice to stop offering Platform 2 TEEPS. That item has clearly been looked at over the course of several years. I'd simply like to know what the main lesson was from the consumer test. Is the difficulty that buyers are dealing with a live heat force, which just generates a great deal of confusion regarding the reduced risk claim? Or was it how the product performed? Any additional detail would help.
Jacek Olczak
executiveHonestly, if you'll permit my phrasing, the problem sat more with the user interface than with anything else. I don't believe that across the duration of the market test, the proposition itself, or how viable that proposition is as a better substitute for smoking and all that follows, was the issue. What's actually at stake is the heat pipe. As you'll recall, in the design, right at the tip of the cigarette-like looking product, there's the heat size, and it needs lighting, correct? So this had to be opened from the paper cup lighting. Then there's the matter of how you put the product out, right, since you must be careful about how you extinguish it. In our view — and really the consumers' view — this was what failed to produce the adoption levels we'd hoped for, particularly when we compare what we've learned from other platforms, above all the T1 platform. So I believe we arrived at a point where that product's design, plus this portion of the technology involving the heat source and how consumers are asked to operate the whole thing, pushed us to conclude that this design component should be shut down. I still think the proposition makes sense, is grasped by the consumer, and holds potential, yet we can't give consumers a product they won't consider convenient to use. Convenience is basically the name of what today's consumers demand, and I think we have to deliver there, particularly since our ambitions include drawing on the equity we've built around IQOS, and IQOS cannot afford a product that has this one. So I suspect we'll return to the P2 at some point. From the outset, you might remember our yearly Investors Day, when we began discussing the vision of growing smoke-free and how many platforms would be required to compare the 1 billion small cars worldwide. This is a proposition aimed more at the conservative audience — people who truly don't wish to entirely walk away from the ritual experience that combustible cigarettes deliver. So as far as our growth prospects for the item go, I don't see it as much of a problem, since we'll be working on it by using a different approach to the design and the technology going forward, going forward. Thus, Vivien, I trust that this addresses what you asked.
Gaurav Jain
analystOkay, so a few things I'd like to ask about. The first relates to your guidance. Your volume growth stands at minus 1:1. You're indicating cigarette pricing will land somewhere between three and four. Then, on that slide of yours, category price mix shows plus three — let's go with three. That ought to bring us to plus 5% to plus 8% revenue growth for FY '22, yet you're putting it at 4% to 6%. That would suggest the category mix uplift ends up smaller in FY '22 compared with FY '21, so could you walk us through the reason for that.
Jacek Olczak
executiveGlad to give it a try and build on that, Gaurav. What we certainly anticipate for 2022 is yet another really healthy gap between how volumes grow and how revenue grows; and yes, on volumes, our guidance has been — anywhere from minus 1% up to plus 1%. So the next thing to figure out is what amount of additional growth we'll deliver, and there's the pricing piece, which sits at 2% to 4%. Keep in mind, 2021 came in at 2.7%. So the bottom of that range isn't dramatically higher than where we landed in 2021. Still, it's fair to say there's room for it to come in better, and that's definitely something we're building into the top end; and beyond that, there's the effect of IQOS growing and what it does to the category, where this favorable mix effect is at work. However, in this case, the mix, together with rolling out across lots of new economies, new geographies and an emerging country, may be influencing that differential. So another very strong differential is what we expect, though not inevitably matching the magnitude of the gap we delivered in 2021. One final point: we mentioned that early on, there's a temporarily heavier weighting toward consumables for IQOS ILUMA Ontario. That plays a role because excise duty in the country where duties are tied to weight comes in higher, and so, since we're bringing the consumable at an equivalent price to it. That can produce, when a switch happens, though only for a while. Again, I view it as temporary, a decrease — a modest dip per stick. So that too may have an effect; so that's essentially what you'll see, plus possibly some effect on price, which will hinge on how many devices we move, on the device mix we move, and on how commercially aggressive we choose to be with device pricing; so a whole set of factors has to be weighed. So when everything is said and done, as is evident looking at that negative 1% to positive 1% alongside the 4% to 6%, our clear aim is to deliver yet another year featuring a really attractive gap separating volume growth from organic revenue growth, and that is precisely where we land.
Gaurav Jain
analystAlright, that's quite useful. My next question concerns the beyond nicotine segment, in which you're going to record $150 million in operating losses during this year, and you also mentioned that you'll keep putting money into it in the years ahead so that the $1 billion revenue target can be reached. So should we take that to mean the losses in FY '23 will come in above what they'll be in FY '22? Or when do you think that segment might break even?
Jacek Olczak
executiveWell, my view is that investment will continue for the next few years — not a couple, but a few years — and we're prepared to make it. I think if you stick with us and hold on until the CAGNY, that's when we'll provide more insight into what we have and how we're thinking about the beyond nicotine wellness and healthcare business, since at that point we'll be able to show which products — concrete products or programs — we intend to pursue, how large the opportunity is, and what kind of investment is involved. But I think the figure we provided for this year, for 2022 in the guidance, gives you the ballpark of the investment we'll be calling for over the couple of years.
Emmanuel Babeau
executiveThis isn't just a single occurrence — it might rise somewhat, though I'm not anticipating a dramatic spike. My sense is that your understanding of the cutout we plan to put money into across a handful of years is well calibrated.
Jared Dinges
analystTo start, I'd like to dig a little deeper into the nicotine pouches. What's the right way for us to think about how big that first rollout in the Nordics will be? And what about the upcoming market entries you mentioned earlier — how should we frame those? Might you look at bringing nicotine pouches into places where they aren't sold at all right now, say certain emerging markets? Then, thinking about what's possible in the U.S., would a PMT filing there be something you'd pursue?
Jacek Olczak
executiveSure — let me set the U.S. to one side for a moment. My view is that nicotine pouches have a really significant part to play when it comes to people who smoke, right? They've shown how versatile they are, and that offering has proven itself across numerous markets. At the outset, we're basically gaining share as we bring this in; then, once we've reworked the product and its packaging and so forth, we'll enter the market where some share was already being sold — clearly not a large amount — but we're beginning in places where we already had a footprint. From there we keep building, just as we always do, through our innovations: we'll study what consumers tell us, figure out what still needs refining; and beyond that first range we've got a product pipeline that we can now push forward much faster, largely because of the therapy acquisition. Fertin, you see, opens up far wider possibilities for us than pouches alone, since Fertin holds some very compelling delivery systems for — around oral delivery. We're aware that Fertin makes nicotine replacement therapies such as gums — nicotine gums — yet they also possess some intriguing additional technologies. So our thinking is that we begin with the pouches, though I expect that across a stretch of time — 2022 — the oral route of delivering nicotine as an alternative to smoking is in fact a highly appealing prospect, and we're genuinely eager to get going on it; therefore we'll move into the geographies, naturally, where pouches aren't available at present. As you're aware, we have a geographic footprint on top of those 70-plus markets where a fairly substantial IQOS infrastructure has been acquired. You're back in the shops, back in digital. You've got CRM, commercial consumer engagement in place. My belief is that we can begin adding to that our array of offerings for smokers in the oral category — a wider oral category, not merely pouches; so this year our focus stays on the pouches. We'll keep widening the presence, yet I think this amounts to more than pouches alone, and I'm very glad we closed the rating acquisition, because it hands us — it speeds up our development by a solid number of years, which otherwise would have had to come about organically.
Jared Dinges
analystUnderstood. Just to expand on that point, then. Would the U.S. PMT application be something you'd look at?
Jacek Olczak
executiveI believe I already gave Bonnie my response to that. The U.S. is a highly appealing market, and in my view it holds strategic significance for us as well; and I genuinely think that in a market as large as the U.S., we honestly need every platform available, since a single platform is what can secure the complete success of pursuing an opportunity; so in the end, yes, though right now our attention lies elsewhere.
Jared Dinges
analystUnderstood. And then the second item, returning to cigarettes and IQOS. Do you folks have any concerns about how price elasticity might play out, particularly among consumers with lower incomes, in light of inflation and where you're situated across most markets, since we typically sit at the premium end? So perhaps you could offer a remark on that?
Jacek Olczak
executiveYeah, so price elasticity is a constant worry, and as we're well aware, at times the price elasticity for tobacco nicotine products runs higher because of the pressures, or income pressures, bearing down on consumers. So right now we have that circumstance in a handful of markets where consumers face income pressure. I mean, I believe a number of these pressures will ease as COVID becomes a thing of the past, and I don't view it as anything systemic. It's quite interesting that you raise this question, because when we examine a market where we're implementing pricing on cigarettes and on HeatSticks, that market possesses a fairly strong body of data from prior increases. I think at present, offerings such as IQOS or smoke-free alternatives tend to display superior elasticity — price elasticity — relative to the traditional cigarette. And as you're aware, I assume, quite well, the price elasticity for cigarettes, set aside by other elements, was rather appealing, and this formed part of constructing the business model. And in fact, right now it appears that the alternative has — not high, but improved elasticity compared with a combustible cigarette. On a separate note, not from an elasticity standpoint but from a purely affordability standpoint, we had already achieved considerable success with IQOS in what are called low middle income countries. Yet we also recognize that to make more substantial inroads, we must bring forward a proposition that squarely tackles the need in the below-price, price segment. And we won't deliver the smokers on our own. And prior to the conclusion of this year, we have plans to trial a different technology that would enable both devices and consumables to become more accessible from an affordability standpoint, while at the same time offering reduction potential as we understand it today. So we are factoring those matters in very seriously. So thank you for your question.
Jacek Olczak
executiveAll right, that call ran longer than we anticipated, yet our results for last year also came in above what we had forecast. Somehow, I suppose, the two balance out. I truly appreciate everyone sticking with us. We'd love to have you join us at our CAGNY presentation, where we'll be able to shed additional light and share further specifics on a handful of areas, such as the wellness healthcare topic we covered earlier today, plus how we're viewing things from a far wider standpoint when it comes to how these categories are developing. And I believe you can hear from my voice and from Emmanuel's voice just how thrilled we are that in '21, we turned in that kind of performance and shape. And even with all the headwinds, which I think we laid out quite clearly, we still see 2022 shaping up as highly successful and rewarding for the two of us. So I'm very grateful for your time, and I hope to see most of you — if not every one of you — at the recovered CAGNY presentation. Thank you, everyone.
Emmanuel Babeau
executiveThanks, everyone. Talk to you shortly.
Nick Rolli
executiveThanks so much. Should you have any additional questions, feel free to reach out to the Investor Relations team, and a quick note that the slides and scripts can be found on the PMI website. Thanks again. Enjoy the rest of your day.
Operator
operatorThanks. That brings us to the end of Philip Morris International's earnings conference call for the fourth quarter and full year 2021. You're welcome to hang up now, and I hope the rest of your day is great.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.